Solithromycin

N/A

Report date: 2026/03/04 20:01:44
NMEQIDP

Base Information

Drug NameSolithromycin
Drug Alias Name索立霉素SolithromycineSolitromicina索利霉素Solithromycinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsProtein biosynthesis inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseasePneumonia, BacterialGonorrhea +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[33] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCubist Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMelinta Therapeutics IncToyama Chemical Co LtdNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseasePneumonia, BacterialGonorrhea +[4] 

Other Information

ATC CodeJ01FA16
Related LinksWikipediaDrugBankKEGG